~~<i id='A72481CB8B'><strike id='A72481CB8B'><tt id='A72481CB8B'><pre id='A72481CB8B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

Wikipedia

author：fashion 2025-08-12 06:44:03 - browse：929

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Wikipedia

hotspot

entertainment

hotspot

entertainment

Medicareisplanningtosend$9billioninlumpsumpaymentstomorethan1,600hospitalsthatparticipateinadrugdisc

WSS

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Pandemic and All Hazards Preparedness Act needs lean update

ALS advocates say criticism of new drugs misses bigger picture

Biden targets hefty hospital 'facility fees' that often surprise patients

Ethical issues complicate the benefits of medical crowdfunding

Eisai exec who led development of Alzheimer’s drug to retire

focus

Wikipedia

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

Wisconsin governor employs partial veto to fund schools for 4 centuries

Sports medicine is finally prioritizing gender equality

Amazon on where the company's health care bets are headed next

Peter Hotez and the public health issue of online harassment

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Anesthesiologist group: stop taking Ozempic before surgery

Stem cell treatment guidelines are released by FDA

Walensky prepares to leave CDC — and Congress — behind

Listen: Biogen's potential pivot, & Illumina's next chapter

hotspot

NIH nominee Bertagnolli will get October confirmation hearing

NIH nominee Bertagnolli will get October confirmation hearing

NIH nominee Bertagnolli will get October confirmation hearing

Eisai exec who led development of Alzheimer’s drug to retire

A rare thyroid diagnosis led to unexpected, all

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

entertainment

hotspot

hotspot

entertainment